Degussa and Hikal sign manufacturing agreement
The Exclusive Synthesis & Catalysts business unit of Degussa has has signed a long-term, non-exclusive agreement with Hikal, of Mumbai, India, for a co-operation on the manufacture of pharmaceutical intermediates and APIs.
The Exclusive Synthesis & Catalysts business unit of Degussa has has signed a long-term, non-exclusive agreement with Hikal, of Mumbai, India, for a co-operation on the manufacture of pharmaceutical intermediates and APIs.
Under this agreement Degussa will provide certain projects to Hikal. In turn, Hikal will provide manufacturing of the respective advanced intermediates and APIs for Degussa.
"We have audited Hikal's facilities and found that its equipment, r&d capabilities and processes meet the rigorous requirements that we set for our own facilities," said Dr Rudolf Hanko, vice president, Exclusive Synthesis business, Degussa. "We can now offer our customers a tailor-made cost mixture of Western and Asian facilities."